Geert D’Haens, Remo Panaccione, Julián Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, W Rachel Duan, Kristina Kligys, Marla Dubinsky
{"title":"117 - 52周的瑞尚单抗皮下维持剂量对于对12周瑞尚单抗诱导反应延迟的中度至重度克罗恩病患者是有效且耐受性良好的","authors":"Geert D’Haens, Remo Panaccione, Julián Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, W Rachel Duan, Kristina Kligys, Marla Dubinsky","doi":"10.1016/s0210-5705(23)00249-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12805,"journal":{"name":"Gastroenterología y Hepatología","volume":"42 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"117 - 52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION\",\"authors\":\"Geert D’Haens, Remo Panaccione, Julián Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, W Rachel Duan, Kristina Kligys, Marla Dubinsky\",\"doi\":\"10.1016/s0210-5705(23)00249-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12805,\"journal\":{\"name\":\"Gastroenterología y Hepatología\",\"volume\":\"42 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterología y Hepatología\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0210-5705(23)00249-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterología y Hepatología","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0210-5705(23)00249-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
117 - 52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION